Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

Author： Foley-Comer Adam J Young Anne-Marie Russell-Yarde Fiona Jordan Paul

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.1, 2011-01, pp. : 3-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist: Implications for Cardiovascular Disease in Patients with Diabetes Mellitus

By Cavender Matthew A. Lincoff A. Michael

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 209-216

Adis International

Access to resources Recommend Favorite

Ezetimibe + low-dose atorvastatin vs high-dose atorvastatin

Inpharma, Vol. 1, Iss. 1580, 2007-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

High-dose atorvastatin for stroke brings a twinkle to the eye

Inpharma, Vol. 1, Iss. 1551, 2006-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

High-dose atorvastatin effective in comorbid CHD, CKD

Inpharma, Vol. 1, Iss. 1635, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

High-dose atorvastatin economically IDEAL in CHD

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 526, 2007-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite